Erratum: Nuclear imaging of molecular processes in cancer (Targeted Oncology DOI: 10.1007/s11523-009-0120-2);Nuclear imaging of molecular processes in cancer

Targeted Oncology

Volumn 4, Issue 3, 2009, Pages 183-197

  Torres Martin De Rosales, Rafael ^a   Årstad, Erik ^b   Blower, Philip J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Apoptosis; Cancer imaging; Glucose metabolism; Hypoxia; Molecular imaging; Nuclear imaging; PET; SPECT

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 6 FLUORODOPA F 18; ARCITUMOMAB TC 99M; ARGINYLGLYCYLASPARTIC ACID; ASTATINE 211; CAPROMAB PENDETIDE IN 111; CARBON 11; ETIDRONIC ACID; ETIDRONIC ACID RE 188; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLTYROSINE F 18; FURIFOSMIN TC 99M; GLYCOPROTEIN P; IODINE 123; IODINE 131; LIPOCORTIN 5; MATRIX METALLOPROTEINASE; MEDRONATE TECHNETIUM TC 99M; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN; PENTETREOTIDE IN 111; RHENIUM 188; SUCCIMER TC 99M; TETROFOSMIN TC 99M; THYMIDINE; THYMIDINE C 11; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID TRANSPORT; ANGIOGENESIS; APOPTOSIS; BONE METASTASIS; CANCER DIAGNOSIS; CARCINOID; CELL PROLIFERATION; DRUG STRUCTURE; DRUG UPTAKE; GLUCOSE METABOLISM; HUMAN; HYPOXIA; ISOTOPE LABELING; MOLECULAR IMAGING; MULTIDRUG RESISTANCE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER;

EID: 72449202610     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-009-0122-0     Document Type: Erratum

References (151)

1. C Riedel O Dohan A De la Vieja CS Ginter N Carrasco 2001 Journey of the iodide transporter NIS: from its molecular identification to its clinical role in cancer Trends Biochem Sci 26 490 496 11504625
2. JK Chung 2002 Sodium iodide symporter: its role in nuclear medicine J Nucl Med 43 1188 1200 12215558
3. P Dubois 2009 Historique de l'imagerie en médecine nucléaire: a history of scintography IRBM 30 40 46 10.1016/j.irbm.2008. 12.002
4. S Banerjee MR Pillai N Ramamoorthy 2001 Evolution of Tc-99m in diagnostic radiopharmaceuticals Semin Nucl Med 31 260 277 11710769
5. ME Phelps 2000 Inaugural article: positron emission tomography provides molecular imaging of biological processes Proc Natl Acad Sci USA 97 9226 9233 97/16/9226 [pii] 10922074
6. MM Ter-Pogossian HN Wagner 1998 A new look at the cyclotron for making short-lived isotopes Semin Nucl Med 28 202 212 9704362
7. P McQuade DJ Rowland JS Lewis MJ Welch 2005 Positron-emitting isotopes produced on biomedical cyclotrons Curr Med Chem 12 807 818 15853713
8. M Bedford MN Maisey 2004 Requirements for clinical PET: comparisons within Europe Eur J Nucl Med Mol Imaging 31 208 221 10.1007/s00259-003-1351-6 15129703 (Pubitemid 38173696)
9. JL Lagrange J Maublant J Darcourt 1995 Bull Cancer (Paris) 82 611 622
10. BN Ganguly NN Mondal M Nandy F Roesch 2009 Some physical aspects of positron annihilation tomography: a critical review J Radioanal Nucl Chem 279 685 698 10.1007/s10967-007-7256-2
11. A Rahmim H Zaidi 2008 PET versus SPECT: strengths, limitations and challenges Nucl Med Commun 29 193 207 18349789
12. JA Patton DW Townsend BF Hutton 2009 Hybrid imaging technology: from dreams and vision to clinical devices Semin Nucl Med 39 247 263 10.1053/j.semnuclmed.2009.03.005 19497402
13. ML Bowen C Orvig 2008 99m-technetium carbohydrate conjugates as potential agents in molecular imaging Chem Commun 41 5077 5091
14. IME Desar CML van Herpen HWM van Laarhoven JO Barentsz WJG Oyen WTA van der Graaf 2009 Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy Cancer Treat Rev 35 309 321 10.1016/j.ctrv.2008.12.001 19136215
15. SJ Gatley 2003 Labeled glucose analogs in the genomic era J Nucl Med 44 1082 1086 12843225
16. 99mTc ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents Radiology 226 465 473 12563141
17. 99mTc]-DTPA-DG) as a potential imaging modality for tumors Appl Radiat Isot 64 342 347 16290170
18. X Chen L Li F Liu B Liu 2006 Synthesis and biological evaluation of technetium-99m-labeled deoxyglucose derivatives as imaging agents for tumor Bioorg Med Chem Lett 16 5503 5506 16931003
19. JM Brown 1999 The hypoxic cell: a target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award Lecture Cancer Res 59 5863 5870 10606224
20. TG Graeber C Osmanian T Jacks DE Housman CJ Koch SW Lowe AJ Giaccia 1996 Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours Nature 379 88 91 10.1038/379088a0 8538748 (Pubitemid 26008141)
21. M Hockel K Schlenger B Aral M Mitze U Schaffer P Vaupel 1996 Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix Cancer Res 56 4509 4515 8813149
22. D Shweiki A Itin D Soffer E Keshet 1992 Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis Nature 359 843 845 1279431
23. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model J Nucl Med 40 177 183 9935074
24. JS Lewis TL Sharp R Laforest Y Fujibayashi MJ Welch 2001 Tumor uptake of copper-diacetyl-bis(N4-methylthiosemicarbazone): effect of changes in tissue oxygenation J Nucl Med 42 655 661 11337556
25. 64Cu-ATSM: a comparison study with FDG Nucl Med Biol 30 529 534 10.1016/S0969-8051(03)00047-7 12831991 (Pubitemid 36776523)
26. 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) J Nucl Med 47 989 998 16741309
27. 60Cu-ATSM: relationship to therapeutic response-a preliminary report Int J Radiat Oncol Biol Phys 55 1233 1238 10.1016/S0360-3016(02)04477-2 12654432 (Pubitemid 36338289)
28. 60Cu-ATSM Eur J Nucl Med Mol Imaging 30 844 850 10.1007/s00259-003- 1130-4 12692685
29. 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET Eur J Nucl Med Mol Imaging 32 764 770 DOI 10.1007/s00259-004-1756-x 15785955 (Pubitemid 41125418)
30. AF Shields JR Grierson BM Dohmen HJ Machulla JC Stayanoff JM Lawhorn-Crews JE Obradovich O Muzik TJ Mangner 1998 Nat Med 4 1334 1336 10.1038/3337 9809561 (Pubitemid 28512118)
31. AF Shields JM Lawhorn-Crews DA Briston S Zalzala S Gadgeel KA Douglas TJ Mangner LK Heilbrun O Muzik 2008 Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Clin Cancer Res 14 4463 4468 10.1158/1078-0432.ccr-07-5243 18628460
32. PL Jager MA de Korte MN Lub-de Hooge A van Waarde KP Koopmans PJ Perik EG de Vries 2005 Molecular imaging: what can be used today Cancer Imaging 5 S27 S32 10.1102/1470-7330.2005.0023 16361133
33. JR Bading AF Shields 2008 Imaging of cell proliferation: status and prospects J Nucl Med 49 Suppl 2 64S 80S 10.2967/jnumed.107.046391 18523066 (Pubitemid 351948037)
34. SM Larson H Schoder 2009 Q J Nucl Med Mol Imaging 53 158 166 19293764
35. AK Buck K Herrmann C Shen T Dechow M Schwaiger HJ Wester 2009 Molecular imaging of proliferation in vivo: positron emission tomography with [(18)F]fluorothymidine Methods 48 205 215 10.1016/j.ymeth.2009.03.009 19318128
36. 18F-FDG J Nucl Med 49 186 194 10.2967/jnumed.107.044966 18199618 (Pubitemid 351225655)
37. 11C]methionine for measuring in vivo protein synthesis rates with PET J Nucl Med 29 1419 1427 3261334
38. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas Mol Imag Biol 10 1 18 10.1007/s11307-007-0115-2
39. P Lindholm M Lapela K Nagren P Lehikoinen H Minn S Jyrkkio 2009 Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer Nucl Med Common 30 30 36
40. 18F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization Sem Nucl Med 37 400 419 10.1053/j.semnuclmed. 2007.08.004 (Pubitemid 47505221)
41. 18F]fluoromethyl-d-tyrosine as a radiotracer for tumor imaging with positron emission tomography Nucl Med Biol 36 295 303
42. 18F] fluoroethyl)-L-Tyrosine for tumor imaging J Nucl Med 40 205 212 9935078
43. F Stockhammer M Plotkin H Amthauer FK van Landeghem C Woiciechowsky 2008 Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas J Neuro-Oncol 88 205 210 10.1007/s11060-008- 9551-3
44. M Wyss S Hofer M Bruehlmeier M Hefti C Uhlmann E Bartschi UW Buettner U Roelcke 2009 Early metabolic responses in temozolomide treated low-grade glioma patients J Neuro-Oncol 10.1007/s11060-009-9896-2
45. 18F]FDG PET in clinical oncology Lancet Oncol 8 822 830 10.1016/S1470-2045(07)70274-7 17765191 (Pubitemid 47308671)
46. HH Boersma BLJH Kietselaer LML Stolk A Bennaghmouch L Hofstra J Narula GAK Heidendal CPM Reutelingsperger 2005 Past, present, and future of annexin A5: from protein discovery to clinical applications J Nucl Med 46 2035 2050 16330568
47. FG Blankenberg 2008 Monitoring of treatment-induced apoptosis in oncology with PET and SPECT Curr Pharm Des 14 2974 2982 18991713
48. 99mTc-annexin V J Nucl Med 46 807 815 15872355
49. K Ohtsuki K Akashi Y Aoka FG Blankenberg S Kopiwoda JF Tait HW Strauss 1999 Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis Eur J Nucl Med 26 1251 1258 10541822
50. FG Blankenberg JL Vanderheyden HW Strauss JF Tait 2006 Radiolabeling of HYNIC-annexin V with technetium-99m for in vivo imaging of apoptosis Nat Protoc 1 108 110 10.1038/nprot2006.17 17406220
51. X Zhang J Rizo TC Sudhof 1998 Mechanism of phospholipid binding by the C2A-domain of synaptotagmin I Biochemistry 37 12395 12403 9730811
52. 99mTc-labeled C2A domain of synaptotagmin I as a target-specific molecular probe for noninvasive imaging of acute myocardial infarction J Nucl Med 47 1367 1374 16883018
53. UA Hirt M Leist 2003 Rapid, noninflammatory and PS-dependent phagocytic clearance of necrotic cells Cell Death Differ 10 1156 1164 14502239
54. H Jin J Varner 2004 Integrins: roles in cancer development and as treatment targets Br J Cancer 90 561 565 14760364
55. 3-integrin expression in vivo Acc Chem Res 42 969 980 10.1021/ar800243b 19489579
56. 99mTc-labeling of hydrazinonicotiniamide-conjugated vitronection receptor antagonist useful for imaging tumors Bioconjugate Chem 12 624 629
57. 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer Bioconjugate Chem 16 1580 1588 10.1021/Bc0501653 (Pubitemid 41681526)
58. B Jia JY Shi Z Yang B Xu ZF Liu HY Zhao S Liu F Wang 2006 Tc-99m-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin alpha(v)beta(3) expression Bioconjugate Chem 17 1069 1076 10.1021/Bc060055b (Pubitemid 44162628)
59. 64Cu-labeled dimeric RGD peptides Mol Imag Biol 6 350 359 10.1016/j.mibio.2004.06.004 (Pubitemid 39243068)
60. 64Cu-labeled tetrameric RGD peptide J Nucl Med 46 1707 1718 16204722
61. M Janssen WJG Oyen LFAG Massuger C Frielink I Dijkgraaf DS Edwards M Radjopadhye FHM Corstens OC Boerman 2002 Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting Cancer Biother Radiopharm 17 641 646 12537667
62. ML Janssen WJ Oyen I Dijkgraaf LF Massuger C Frielink DS Edwards M Rajopadhye H Boonstra FH Corstens OC Boerman 2002 Turmor targeting with radiolabeled alpha-v-beta-3 integrin binding peptides in a nude mouse model Cancer Res 62 6146 6151 12414640
63. G Thumshirn U Hersel SL Goodman H Kessler 2003 Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation Chem Eur J 9 2717 2725 10.1002/chem.200204304
64. 3-integrin expression J Nucl Med 45 1776 1783 15471848
65. 3 integrin by multimerisation of RGD peptides Eur J Nucl Med Mol Imaging 34 267 273 16909226 (Pubitemid 46147510)
66. A Beer M Schwaiger 2008 Imaging of integrin αvβ3 expression Cancer Metastasis Rev 27 631 644 18523730
67. 18F]galacto-RGD positron emission tomography Neuro Oncol 10.1215/15228517-2009-024 19401596
68. 18F-AH111585 in breast cancer patients J Nucl Med 49 879 886 10.2967/jnumed.107.049452 18483090 (Pubitemid 351793427)
69. Glaser M, Solbakken M, Turton D, Pettitt R, Barnett J, Arukwe J, Karlsen H, Cuthbertson A, Luthra S, Årstad E (2008) Methods for (18)F-labeling of RGD peptides: comparison of aminooxy [(18)F]fluorobenzaldehyde condensation with 'click labeling' using 2-[(18)F]fluoroethylazide, and S-alkylation with [ (18)F]fluoropropanethiol. Amino Acids, Nov. 15. doi: 10.1007/s00726-008-0200-0
70. MM Gottesman 1993 How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture Cancer Res 53 747 754 8094031
71. B Tan D Piwnica-Worms L Ratner 2000 Multidrug resistance transporters and modulation Curr Opin Oncol 12 450 458 10975553
72. SPC Cole G Bhardwaj JH Gerlach JE Mackie CE Grant KC Almquist AJ Stewart EU Kurz AMV Duncan RG Deeley 1992 Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 258 1650 1654 1360704
73. JR Ballinger 2001 Imaging multidrug resistance with radiolabeled substrates for P-glycoprotein and multidrug resistance protein Cancer Biother Radiopharm 16 1 7 11279792
74. S DelVecchio A Ciarmiello L Pace MI Potena MV Carriero C Mainolfi R Thomas G DAiuto T Tsuruo M Salvatore 1997 Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients J Nucl Med 38 1348 1351
75. BI Sikic GA Fisher BL Lum J Halsey L BeketicOreskovic G Chen 1997 Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein Cancer Chemother Pharm 40 S13 S19
76. 99mTc-MIBI and proliferation in untreated breast cancer Eur J Nucl Med 26 1166 1166
77. 11C]verapamil and PET J Cereb Blood Flow Metab 27 424 433 10.1038/sj.jcbfm.9600349 16757979 (Pubitemid 46148468)
78. 11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation Nucl Med Biol 30 747 751 S0969805103000787 [pii] 14499333
79. 11C]verapamil kinetics in human tissues Eur J Clin Pharm 56 827 829
80. Fleish H (1995) Bisphosphonates in bone disease: from the laboratory to the patient. Parthenon Publishing Group, London
81. Å Handeland MW Lindegaard D-E Heggli 1989 Biodistribution of anionic separated MDP complexes from different MDP preparations Eur J Nucl Med Mol Imaging 15 609 611
82. 18F-fluorodeoxyglucose positron emission tomography Q J Nucl Med 45 47 52 11456375
83. 18F fluoride PET-CT: a comparative study Eur J Nucl Med Mol Imaging 35 1766 1774 10.1007/s00259-008-0788-z 18465129
84. BK Giersing MT Rae M CarballidoBrea RA Williamson PJ Blower 2001 In-111-DTPA-N-TIMP-2: a radiopharmaceutical for imaging matrix metalloproteinase expression in tumors Bioconjugate Chem 12 964 971 bc010028f [pii]
85. M Schafers B Riemann K Kopka H-J Breyholz S Wagner KP Schafers MP Law O Schober B Levkau 2004 Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall Circulation 109 2554 2559 10.1161/01.cir.0000129088.49276. 83 15123523 (Pubitemid 38720556)
86. J Buscombe H Hirji C Witney-Smith 2008 Nuclear medicine in the management of thyroid disease Expert Rev Anticancer Ther 8 1425 1431 10.1586/14737140.8.9. 1425 18759694
87. 124I PET Eur J Nucl Med Mol Imaging 35 502 508 10.1007/s00259-007- 0601-4 18026950
88. E Dadachova B Bouzahzah LS Zuckier RG Pestell 2002 Rhenium-188 as an alternative to iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS) Nucl Med Biol 29 13 18 11786271
89. LS Zuckier O Dohan Y Li CJ Chang N Carrasco E Dadachova 2004 Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo J Nucl Med 45 500 507 15001694
90. 211At a-particle radiotherapy for undifferentiated thyroid cancer Acta Radiol 376 suppl. 174 175
91. MR Zalutsky GV Vaidyanathan 2000 Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherpay Curr Pharmaceutical Des 6 1433 1455
92. A Boubaker AB Delaloye 2008 MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma Q J Nucl Med Mol Imaging 52 388 402 19088693
93. SG DuBois KK Matthay 2008 Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma Nucl Med Biol 35 S35 S48 10.1016/j.nucmedbio.2008.05. 002 18707633
94. G Vaidyanathan 2008 Meta-iodobenzylguanidine and analogues: chemistry and biology Q J Nucl Med Mol Imaging 52 351 368 19088690
95. AB Apolo N Pandit-Taskar MJ Morris 2008 Novel tracers and their development for the imaging of metastatic prostate cancer J Nucl Med 49 2031 2041 10.2967/jnumed.108.050658 18997047
96. T Hara N Kosaka H Kishi 1998 PET imaging of prostate cancer using carbon-11-choline J Nucl Med 39 990 995 9627331
97. 11C-choline PET/CT J Nucl Med 47 1249 1254 47/8/1249 [pii] 16883001
98. 11C-choline PET and PET/CT in patients with suspected prostate cancer Eur J Nucl Med Mol Imag 34 45 53 10.1007/s00259-006-0190-7 (Pubitemid 44885553)
99. 11C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer Nucl Med Biol 35 689 695 10.1016/j.nucmedbio.2008.05. 006 18678354
100. 18F-fluoride in bone imaging with emphasis on prostate and breast Sem Nucl Med 36 7392 10.1053/j.semnuclmed.2005.09.002 (Pubitemid 41782168)
101. M Picchio C Crivellaro G Giovacchini L Gianolli C Messa 2009 PET-CT for treatment planning in prostate cancer Q J Nucl Med Mol Imaging 53 245 268 19293771
102. A Signore A Annovazzi M Chianelli F Corsetti C Van de Wiele RN Watherhouse F Scopinaro 2001 Peptide radiopharmaceuticals for diagnosis and therapy Eur J Nucl Med 28 1555 1565 11685500
103. G Lucignani 2008 Labeling peptides with PET radiometals: Vulcan's forge Eur J Nucl Med Mol Imaging 35 209 215 18038132
104. J Fichna A Janecka 2003 Synthesis of target-specific radiolabeled peptides for diagnostic imaging Bioconjug Chem 14 3 17 12526687
105. LM De Leon-Rodriguez Z Kovacs 2008 The synthesis and chelation chemistry of DOTA-peptide conjugates Bioconjug Chem 19 391 402 18072717
106. Z Win A Al-Nahhas D Rubello MD Gross 2007 Somatostatin receptor PET imaging with Gallium-68 labeled peptides Q J Nucl Med Mol Imaging 51 244 250 17464267 (Pubitemid 47181084)
107. D Hoyer GI Bell M Berelowitz J Epelbaum W Feniuk PPA Humphrey AM Ocarroll YC Patel A Schonbrunn JE Taylor T Reisine 1995 Classification and nomenclature of somatostatin receptors Trends Pharmacol Sci 16 86 88 7792934
108. AV Schally 1988 Oncological applications of somatostatin analogs Cancer Res 48 6977 6985 2903792
109. W Bauer U Briner W Doepfner R Haller R Huguenin P Marbach TJ Petcher J Pless 1982 SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action Life Sci 31 1133 1140 6128648
110. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor- positive tumors: preclinical evaluation and comparison with 111In-octreotide J Nucl Med 41 1114 1119 10855644
111. 99mTc-tricine-HYNIC-d -Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-d -Phe1-octreotide Eur J Nucl Med Mol Imaging 27 628 637
112. A AL-Nahhas Z Win T Szyszko A Singh S Khan D Rubello 2007 What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging 34 1897 1901 17713764 (Pubitemid 350212142)
113. P Antunes M Ginj H Zhang B Waser RP Baum JC Reubi H Maecke 2007 Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34 982 993 17225119
114. M Hofmann H Maecke AR Borner E Weckesser P Schoffski ML Oei J Schumacher M Henze A Heppeler GJ Meyer WH Knapp 2001 Biokinetics and imaging with the somatostatin receptor PET radioligand Ga-68-DOTATOC: preliminary data Eur J Nucl Med 28 1751 1757 11734911
115. M Gabriel C Decristoforo D Kendler G Dobrozemsky D Heute C Uprimny P Kovacs E Von Guggenberg R Bale IJ Virgolini 2007 Ga-68-DOTA-Tyr(3)-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT J Nucl Med 48 508 518 17401086
116. JC Reubi U Laderach B Waser JO Gebbers P Robberecht JA Laissue 2000 Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin Cancer Res 60 3105 3112 10850463
117. ML Thakur MR Aruva J Gariepy P Acton S Rattan S Prasad E Wickstrom A Alavi 2004 PET imaging of oncogene overexpression using Cu-64-vasoactive intestinal peptide (VIP) analog: comparison with Tc-99m-VIP analog J Nucl Med 45 1381 1389 15299065
118. K Zhang MR Aruva N Shanthly CA Cardi S Rattan C Patel C Kim PA McCue E Wickstrom ML Thakur 2008 PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer J Nucl Med 49 112 121 18077536
119. JP Smith TE Solomon 1988 Effects of gastrin, proglumide, and somatostatin on growth of human-colon cancer Gastroenterology 95 1541 1548 2903111
120. JF Rehfeld WW Vansolinge 1994 The tumor biology of gastrin and cholecystokinin Adv Cancer Res 63 295 347 8036989
121. I Camby I Salmon C Oiry JC Galleyrand N Nagy A Danguy J Brotchi JL Pasteels J Martinez R Kiss 1996 The influence of gastrin and/or cholecystokinin antagonists on the proliferation of three human astrocytic tumor cell lines Neuropeptides 30 433 437 8923504
122. GJ Dockray 2000 Gastrin, growth, and colon neoplasia Gut 47 747 748 11076869
123. SA Wank JR Pisegna A Deweerth 1992 Brain and gastrointestinal cholecystokinin receptor family-structure and functional expression Proc Nat Acad Sci USA 89 8691 8695 1528881
124. AS Kopin YM Lee EW Mcbride LJ Miller M Lu HY Lin LF Kolakowski M Beinborn 1992 Expression cloning and characterization of the canine parietal-cell gastrin receptor Proc Nat Acad Sci USA 89 3605 3609 1373504
125. JC Reubi B Waser JC Schaer U Laederach J Erion A Srinivasan MA Schmidt JE Bugaj 1998 Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo Eur J Nucl Med 25 481 490 9575243
126. JC Reubi JC Schaer B Waser 1997 Cholecystokinin (CCK)-A and CCK-B gastrin receptors in human tumors Cancer Res 57 1377 1386 9102227
127. TM Behr N Jenner M Behe C Angerstein S Gratz F Raue W Becker 1999 Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors J Nucl Med 40 1029 1044 10452322
128. RW Alexander JR Upp GJ Poston V Gupta CM Townsend JC Thompson 1988 Effects of bombesin on growth of human small cell lung-carcinoma in vivo Cancer Res 48 1439 1441 2830965
129. J Nelson M Donnelly B Walker J Gray C Shaw RF Murphy 1991 Bombesin stimulates proliferation of human breast-cancer cells in culture Brit J Cancer 63 933 936 2069848
130. QMJ Wang JA Knezetic AV Schally PM Pour TE Adrian 1996 Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway Int J Cancer 68 528 534 8945626
131. T Moody C Pert A Gazdar D Carney J Minna 1981 High levels of intracellular bombesin characterize human small-cell lung carcinoma Science 214 1246 1248 6272398
132. ER Spindel E Giladi P Brehm RH Goodman TP Segerson 1990 Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/gastrin-releasing peptide receptor Mol Endocrinol 4 1956 1963 1707129
133. E Wada J Way H Shapira K Kusano AM Lebacq-Verheyden D Coy R Jensen J Battey 1991 cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor Neuron 6 421 430 1848080
134. Z Fathi M Corjay H Shapira E Wada R Benya R Jensen J Viallet E Sausville J Battey 1993 BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells J Biol Chem 268 5979 5984 8383682
135. SR Nagalla BJ Barry KC Creswick P Eden JT Taylor ER Spindel 1995 Cloning of a receptor for amphibian [Phe13]bombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4) Proc Nat Acad Sci USA 92 6205 6209 7597102
136. KE Baidoo K-S Lin Y Zhan P Finley U Scheffel HN Wagner 1998 Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues Bioconjugate Chem 9 218 225
137. WAP Breeman BF MDJ DJ Bernard AS Kwekkeboom ME van der Pluijm LJ Hofland TJ Visser EP Krenning 1999 Pre-clinical evaluation of bombesin, a new radioligand for bombesin-receptor scintigraphy Int J Cancer 83 657 663 10521803
138. B Nock A Nikolopoulou E Chiotellis G Loudos D Maintas J Reubi T Maina 2003 [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging Eur J Nucl Med Mol Imaging 30 247 258 12552343
139. C Van de Wiele F Dumont RA Dierckx SH Peers JR Thornback G Slegers H Thierens 2001 Biodistribution and dosimetry of 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies J Nucl Med 42 1722 1727 11696645
140. C Van de Wiele F Dumont R Vanden Broecke W Oosterlinck V Cocquyt R Serreyn S Peers J Thornback G Slegers RA Dierckx 2000 Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study European J Nucl Med Mol Imaging 27 1694 1699
141. M Gotthardt J van Eerd-Vismale WJG Oyen M de Jong H Zhang E Rolleman HR Maecke M Behe O Boerman 2007 Indication for different mechanisms of kidney uptake of radiolabeled peptides J Nucl Med 48 596 601 17401097
142. HM Lamb D Faulds 1998 Capromab pendetide-a review of its use as an imaging agent in prostate cancer Drugs Aging 12 293 304 9571393
143. DM Goldenberg FH Deland 1984 Clinical studies of prostatic cancer imaging with radiolabeled antibodies against prostatic acid-phosphatase Urol Clin North Am 11 277 281 6328719
144. DH Peters A Fitton 1995 Satumomab pendetide-a preliminary review of its use in the diagnosis of colorectal and ovarian cancer Clin Immunother 3 395 408
145. WA Wegener N Petrelli A Serafini DM Goldenberg 2000 Safety and efficacy of arcitumomab imaging in colorectal cancer after repeated administration J Nucl Med 41 1016 1020 10855627
146. HB Breitz A Tyler MJ Bjorn T Lesley PL Weiden 1997 Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy Clin Nucl Med 22 615 620 9298295
147. DM Goldenberg RM Sharkey 2007 Novel radiolabeled antibody conjugates Oncogene 26 3734 3744 17530026
148. JL Dearling RB Pedley 2007 Technological advances in radioimmunotherapy Clin Oncol (Royal College of Radiologists) 19 457 469
149. 99mTc-(V)-DMSA uptake is mediated by NaPi cotransporter type III in tumour cell lines Eur J Nucl Med Mol Imaging 31 77 84 14557898
150. PJ Blower J Singh SEM Clarke 1991 The chemical identity of pentavalent technetium-99m-dimercaptosuccinic acid J Nucl Med 32 845 849 1850782
151. PJ Blower AS Lam MJ O'Doherty AG Kettle AJ Coakley FF Knapp Jr 1998 Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: synthesis and preliminary animal and human studies Eur J Nucl Med 25 613 621 9618576